Azenta, Inc. AZTA
We take great care to ensure that the data presented and summarized in this overview for Azenta, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AZTA
View all-
Black Rock Inc. New York, NY4.81MShares$143 Million0.01% of portfolio
-
Politan Capital Management LP New York, NY4.62MShares$137 Million12.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.44MShares$132 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.52MShares$75 Million0.02% of portfolio
-
State Street Corp Boston, MA1.71MShares$50.8 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.7MShares$50.5 Million0.02% of portfolio
-
Conestoga Capital Advisors, LLC1.47MShares$43.7 Million0.68% of portfolio
-
Allspring Global Investments Holdings, LLC1.29MShares$38.3 Million0.07% of portfolio
-
Gw&K Investment Management, LLC Boston, MA1.13MShares$33.6 Million0.29% of portfolio
-
Geode Capital Management, LLC Boston, MA1.02MShares$30.4 Million0.0% of portfolio
Latest Institutional Activity in AZTA
Top Purchases
Top Sells
About AZTA
Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold sample management systems for compound and biological sample storage; equipment for sample preparation and handling; consumables; and instruments that help customers in managing samples throughout their research discovery and development workflows. The Life Sciences Services segment provides comprehensive sample management programs, integrated cold chain solutions, informatics, and sample-based laboratory services to advance scientific research and support drug development. This segment's services include sample storage, genomic sequencing, gene synthesis, laboratory processing, laboratory analysis, biospecimen procurement, and other support services. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Chelmsford, Massachusetts.
Insider Transactions at AZTA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 24
2025
|
John Marotta President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
122,269
+36.01%
|
-
|
|
Nov 24
2025
|
Olga Pirogova SVP and CHRO |
BUY
Grant, award, or other acquisition
|
Direct |
16,303
+33.04%
|
-
|
|
Nov 24
2025
|
Lawrence Y. Lin EVP, CFO and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
36,681
+31.53%
|
-
|
|
Nov 24
2025
|
Ginger Zhou SVP and GM, Multiomics |
BUY
Grant, award, or other acquisition
|
Direct |
13,042
+25.18%
|
-
|
|
Nov 24
2025
|
Ephraim Starr SVP, Gen Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
34,235
+32.22%
|
-
|
|
Nov 14
2025
|
Olga Pirogova SVP and CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,553
-8.49%
|
$45,037
$29.75 P/Share
|
|
Nov 14
2025
|
Ginger Zhou SVP and GM, Multiomics |
SELL
Payment of exercise price or tax liability
|
Direct |
1,118
-4.17%
|
$32,422
$29.75 P/Share
|
|
Nov 14
2025
|
John Marotta President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,980
-10.36%
|
$318,420
$29.75 P/Share
|
|
Nov 14
2025
|
Lawrence Y. Lin EVP, CFO and Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,039
-6.6%
|
$88,131
$29.75 P/Share
|
|
Sep 10
2025
|
John Marotta President and CEO |
SELL
Open market or private sale
|
Direct |
316
-0.3%
|
$9,164
$29.41 P/Share
|
|
Aug 12
2025
|
Ginger Zhou SVP and GM, Multiomics |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,085
-3.89%
|
$30,380
$28.54 P/Share
|
|
Aug 12
2025
|
Olga Pirogova SVP and CHRO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,085
-5.6%
|
$30,380
$28.54 P/Share
|
|
Aug 11
2025
|
Lawrence Y. Lin EVP, CFO and Treasurer |
BUY
Open market or private purchase
|
Direct |
2,500
+5.15%
|
$67,500
$27.96 P/Share
|
|
Jun 02
2025
|
John Marotta President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+0.92%
|
$25,000
$25.99 P/Share
|
|
May 30
2025
|
Alan J Malus |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+41.33%
|
$312,000
$26.65 P/Share
|
|
May 20
2025
|
William L Cornog |
BUY
Grant, award, or other acquisition
|
Indirect |
2,748
+11.22%
|
$74,196
$27.37 P/Share
|
|
May 19
2025
|
William L Cornog |
BUY
Grant, award, or other acquisition
|
Indirect |
4,152
+17.93%
|
$107,952
$26.98 P/Share
|
|
May 16
2025
|
William L Cornog |
BUY
Grant, award, or other acquisition
|
Indirect |
100
+0.67%
|
$2,600
$26.5 P/Share
|
|
May 15
2025
|
Ephraim Starr SVP, Gen Counsel & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
37,779
+50.0%
|
$982,254
$26.71 P/Share
|
|
May 09
2025
|
John Marotta President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,796
+1.66%
|
$48,492
$27.84 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 352K shares |
|---|---|
| Open market or private purchase | 2.92K shares |
| Payment of exercise price or tax liability | 16.7K shares |
|---|---|
| Open market or private sale | 633 shares |
| Sale (or disposition) back to the issuer | 2.31K shares |